Which has the lower trailing P/E, HRMY or LQDA?

HRMY has the lower trailing P/E: HRMY trades at 12.94 and LQDA at 19.55. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, HRMY or LQDA?

Over the past five years, LQDA grew revenue faster — HRMY at a 32.47% CAGR versus LQDA at 128.77%.

Is HRMY or LQDA more profitable?

LQDA runs the higher net margin — HRMY at 18.88% versus LQDA at 30.74%.

How have HRMY and LQDA total returns compared?

Over the past 5 years, HRMY delivered 0.91% and LQDA delivered 59.01% annualized total return. Past performance doesn't predict future results.

Harmony Biosciences Holdings, Inc. (HRMY) vs Liquidia Corporation (LQDA)

A side-by-side comparison of Harmony Biosciences Holdings, Inc. and Liquidia Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

HRMY

Harmony Biosciences Holdings, Inc.

$2.31B

$39.86HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT

LQDA

Liquidia Corporation

$2.38B

$26.76HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT

Total return — HRMY vs LQDA

growth of $100 · dividends reinvested · last 6y

HRMY +7.9% (+1.3%/yr)LQDA +378.2% (+29.8%/yr)LQDA compounded faster over this window

HRMY LQDA

HRMY vs LQDA: by the numbers

•LQDA is the larger company ($2.38B vs $2.31B market cap).
•HRMY trades at the lower trailing earnings multiple (12.94 vs 19.55 P/E), one valuation lens rather than an overall verdict.
•LQDA converts more revenue to profit (30.74% vs 18.88% net margin).
•LQDA grew revenue faster over the past five years (128.77% vs 32.47% CAGR).

Metrics side by side

Valuation

Metric	HRMY	LQDA
P/E ratio	12.94	19.55
Forward P/E	10.11	10.77
P/S ratio	2.40	5.28
P/B ratio	2.31	12.20
EV / EBITDA	7.47	13.06
FCF yield	15.38%	2.54%

Profitability

Metric	HRMY	LQDA
Gross margin	75.42%	92.48%
Operating margin	24.03%	-32.45%
Net margin	18.88%	30.74%
ROE	18.14%	71.04%
ROIC	14.96%	46.99%

Growth (annualized)

Metric	HRMY	LQDA
Revenue CAGR (5Y)	32.47%	128.77%
FCF CAGR (5Y)	48.43%	N/A
Total return CAGR (5Y)	0.91%	59.01%

Frequently asked

Which has the lower trailing P/E, HRMY or LQDA?: HRMY has the lower trailing P/E: HRMY trades at 12.94 and LQDA at 19.55. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, HRMY or LQDA?: Over the past five years, LQDA grew revenue faster — HRMY at a 32.47% CAGR versus LQDA at 128.77%.
Is HRMY or LQDA more profitable?: LQDA runs the higher net margin — HRMY at 18.88% versus LQDA at 30.74%.
How have HRMY and LQDA total returns compared?: Over the past 5 years, HRMY delivered 0.91% and LQDA delivered 59.01% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HRMY analysis Full LQDA analysis Interactive comparison tool

Dig into the metrics

Harmony Biosciences P/E ratio Liquidia P/E ratio Harmony Biosciences ROE Liquidia ROE Harmony Biosciences operating margin Liquidia operating margin Harmony Biosciences revenue growth Liquidia revenue growth Harmony Biosciences free cash flow Liquidia free cash flow

Harmony Biosciences & Liquidia appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.